BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33114380)

  • 21. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-Osteoblasts Stimulate Migration of Breast Cancer Cells via the HGF/MET Pathway.
    Vallet S; Bashari MH; Fan FJ; Malvestiti S; Schneeweiss A; Wuchter P; Jäger D; Podar K
    PLoS One; 2016; 11(3):e0150507. PubMed ID: 26934743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway.
    Yang Y; Blair HC; Shapiro IM; Wang B
    J Biol Chem; 2015 Jul; 290(27):16918-28. PubMed ID: 25979341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.
    Hjertner O; Torgersen ML; Seidel C; Hjorth-Hansen H; Waage A; Børset M; Sundan A
    Blood; 1999 Dec; 94(11):3883-8. PubMed ID: 10572104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients' bone marrow stromal cells co-cultured with myeloma cells.
    Zdzisińska B; Bojarska-Junak A; Walter-Croneck A; Kandefer-Szerszeń M
    Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):153-63. PubMed ID: 20157786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling.
    Li S; Yang B; Teguh D; Zhou L; Xu J; Rong L
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of moderate intensity static magnetic fields on osteoclastic differentiation in mouse bone marrow cells.
    Kim EC; Park J; Noh G; Park SJ; Noh K; Kwon IK; Ahn SJ
    Bioelectromagnetics; 2018 Jul; 39(5):394-404. PubMed ID: 29709064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
    Thummuri D; Naidu VGM; Chaudhari P
    J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YAP1 inhibits the induction of TNF-α-stimulated bone-resorbing mediators by suppressing the NF-κB signaling pathway in MC3T3-E1 cells.
    Yang B; Sun H; Xu X; Zhong H; Wu Y; Wang J
    J Cell Physiol; 2020 May; 235(5):4698-4708. PubMed ID: 31642068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC.
    Ono K; Kamiya S; Akatsu T; Nakamura C; Li M; Amizuka N; Matsumoto K; Nakamura T; Kugai N; Wada S
    Bone; 2006 Jul; 39(1):27-34. PubMed ID: 16459153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-κb and Nfatc1 Activities.
    Jiang C; Shang J; Li Z; Qin A; Ouyang Z; Qu X; Li H; Tian B; Wang W; Wu C; Wang J; Dai M
    J Cell Physiol; 2016 Jan; 231(1):142-51. PubMed ID: 26060084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression.
    Kwak HB; Kim HS; Lee MS; Kim KJ; Choi EY; Choi MK; Kim JJ; Cho HJ; Kim JW; Bae JM; Kim YK; Park BH; Ha H; Chun CH; Oh J
    Biol Pharm Bull; 2009 Jan; 32(1):45-50. PubMed ID: 19122279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis.
    Saito K; Ohara N; Hotokezaka H; Fukumoto S; Yuasa K; Naito M; Fujiwara T; Nakayama K
    J Biol Chem; 2004 Apr; 279(14):13555-63. PubMed ID: 14729681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
    Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.